MIPI Molecular Insight Pharmaceuticals (MM)

BeaconEquity.com announces an investment report featuring biotech company Molecular Insight Pharmaceuticals Inc. (Nasdaq:MIPI). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision. 

The full report is available at: http://www.beaconequity.com/i/MIPI

Get our alerts BEFORE the rest of the market.  Follow us on Twitter: http://twitter.com/BeaconEquity

Molecular Insight Pharmaceuticals Inc. (MIPI) is a biopharmaceutical company focused on the research, development and commercialization of molecular imaging pharmaceuticals and targeted radiotherapeutics designed to improve patient diagnosis, treatment and management. The Company's molecular imaging radiopharmaceutical product candidate Zemiva is for the diagnosis of cardiac ischemia (insufficient blood flow to the heart muscle) and its other imaging candidate, Trofex, is in development for the detection of metastatic prostate cancer. Its radiotherapeutic product candidates, Azedra and Onalta, are both radiolabeled small molecules being developed for the treatment of neuroendocrine cancers.

Message Board Search for MIPI:  http://www.boardcentral.com/boards/MIPI

In the report, the analyst notes:

"For the third quarter of 2009, the Company reported a net loss of $21.4 million, compared to a net loss of $24.7 million in the third quarter of 2008. Third quarter operating expenses of $16.4 million declined by 17%, or $3.4 million, from the prior year due to a decrease in research and development expenses of $2.9 million and in general and administrative expenses of $0.5 million.

"MIPI last month announced that David R. Epstein and Yvonne Greenstreet, M.D., have resigned from its board of directors. Epstein recently was promoted to head of Pharmaceuticals at Novartis and is relocating to Switzerland. Greenstreet serves as senior vice president and chief of strategy, research and development at GlaxoSmithKline."

To read the entire report visit: http://www.beaconequity.com/i/MIPI

See what investors are saying about MIPI at penny stock forum

BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

CONTACT:  Beacon Equity Research

          Jeff Bishop

          (469)-252-3505 

          press@beaconequity.com